Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial

医学 阿那曲唑 乳腺癌 芳香化酶抑制剂 内科学 肿瘤科 激素替代疗法(女性对男性) 妇科 性激素结合球蛋白 睾酮(贴片) 临床终点 癌症 随机对照试验 三苯氧胺 激素 雄激素
作者
Jack Cuzick,Kim Chu,Brian Keevil,Adam R. Brentnall,Anthony Howell,Nicholas Zdenkowski,Bernardo Bonanni,Sibylle Loibl,Kaija Holli,D. Gareth Evans,Steve Cummings,Mitch Dowsett
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:25 (1): 108-116 被引量:5
标识
DOI:10.1016/s1470-2045(23)00578-8
摘要

Summary

Background

An increased risk of breast cancer is associated with high serum concentrations of oestradiol and testosterone in postmenopausal women, but little is known about how these hormones affect response to endocrine therapy for breast cancer prevention or treatment. We aimed to assess the effects of serum oestradiol and testosterone concentrations on the efficacy of the aromatase inhibitor anastrozole for the prevention of breast cancer in postmenopausal women at high risk.

Methods

In this case-control study we used data from the IBIS-II prevention trial, a randomised, controlled, double-blind trial in postmenopausal women aged 40–70 years at high risk of breast cancer, conducted in 153 breast cancer treatment centres across 18 countries. In the trial, women were randomly assigned (1:1) to receive anastrozole (1 mg/day, orally) or placebo daily for 5 years. In this pre-planned case-control study, the primary analysis was the effect of the baseline oestradiol to sex hormone binding globulin (SHBG) ratio (oestradiol–SHBG ratio) on the development of all breast cancers, including ductal carcinoma in situ (the primary endpoint in the trial). Cases were participants in whom breast cancer was reported after trial entry and until the cutoff on Oct 22, 2019, and who had valid blood samples and no use of hormone replacement therapy within 3 months of trial entry or during the trial. For each case, two controls without breast cancer were selected at random, matched on treatment group, age (within 2 years), and follow-up time (at least that of the matching case). For each treatment group, we applied a multinominal logistic regression likelihood-ratio trend test to assess what change in the proportion of cases was associated with a one-quartile change in hormone ratio. Controls were used only to determine quartile cutoffs. Profile likelihood 95% CIs were used to indicate the precision of estimates. A secondary analysis also investigated the effect of the baseline testosterone–SHBG ratio on breast cancer development. We also assessed relative benefit of anastrozole versus placebo (calculated as 1 – the ratio of breast cancer cases in the anastrozole group to cases in the placebo group). The trial was registered with ISRCTN (number ISRCTN31488319) and completed recruitment on Jan 31, 2012, but long-term follow-up is ongoing.

Findings

3864 women were recruited into the trial between Feb 2, 2003, and Jan 31, 2012, and randomly assigned to receive anastrozole (n=1920) or placebo (n=1944). Median follow-up time was 131 months (IQR 106–156), during which 85 (4·4%) cases of breast cancer in the anastrozole group and 165 (8·5%) in the placebo group were identified. No data on gender, race, or ethnicity were collected. After exclusions, the case-control study included 212 participants from the anastrozole group (72 cases, 140 controls) and 416 from the placebo group (142 cases, 274 controls). A trend of increasing breast cancer risk with increasing oestradiol–SHBG ratio was found in the placebo group (trend per quartile 1·25 [95% CI 1·08 to 1·45], p=0·0033), but not in the anastrozole group (1·06 [0·86 to 1·30], p=0·60). A weaker effect was seen for the testosterone–SHBG ratio in the placebo group (trend 1·21 [1·05 to 1·41], p=0·011), but again not in the anastrozole group (trend 1·18 [0·96 to 1·46], p=0·11). A relative benefit of anastrozole was seen in quartile 2 (0·55 [95% CI 0·13 to 0·78]), quartile 3 (0·54 [0·22 to 0·74], and quartile 4 (0·56 [0·23 to 0·76]) of oestradiol–SHBG ratio, but not in quartile 1 (0·18 [–0·60 to 0·59]).

Interpretation

These results suggest that serum hormones should be measured more routinely and integrated into risk management decisions. Measuring serum hormone concentrations is inexpensive and might help clinicians differentiate which women will benefit most from an aromatase inhibitor.

Funding

Cancer Research UK, National Health and Medical Research Council (Australia), Breast Cancer Research Foundation, and DaCosta Fund.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
用头打碟发布了新的文献求助10
刚刚
y_y发布了新的文献求助10
刚刚
冷一泽发布了新的文献求助10
1秒前
1秒前
传奇3的应助被减减采纳,获得10
1秒前
indigo完成签到 ,获得积分10
1秒前
1秒前
咿呀完成签到,获得积分10
1秒前
许琦完成签到,获得积分10
1秒前
理穆辛完成签到 ,获得积分10
1秒前
gzh完成签到,获得积分10
1秒前
xucc的应助被粉色棉毛裤采纳,获得10
2秒前
yyy完成签到 ,获得积分10
2秒前
燕不留声完成签到 ,获得积分10
2秒前
阿莴鹅完成签到,获得积分10
2秒前
2秒前
言目木完成签到,获得积分10
2秒前
谌坚完成签到 ,获得积分10
2秒前
2秒前
温暖砖头发布了新的文献求助10
2秒前
小二郎的应助被cai采纳,获得10
2秒前
linlin完成签到,获得积分10
3秒前
3秒前
自然尔风发布了新的文献求助10
3秒前
Lucas的应助被那天晚上我竟然采纳,获得10
3秒前
CC完成签到,获得积分10
3秒前
3秒前
周海涛发布了新的文献求助10
4秒前
在路上完成签到,获得积分10
4秒前
星星之火完成签到,获得积分10
4秒前
嘉梦完成签到,获得积分10
4秒前
yw发布了新的文献求助10
4秒前
4秒前
wk完成签到,获得积分10
5秒前
端庄千山完成签到 ,获得积分10
5秒前
潇洒的世界完成签到,获得积分10
5秒前
打打的应助被Una采纳,获得15
6秒前
6秒前
矢思然完成签到,获得积分10
6秒前
研友_VZG7GZ的应助被Una采纳,获得15
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159351
求助须知:如何正确求助?哪些是违规求助? 9554821
关于积分的说明 21722386
捐赠科研通 7749097
什么是DOI,文献DOI怎么找? 3427199
关于科研通互助平台的介绍 2552150
邀请新用户注册赠送积分活动 2471530